Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.

Abstract: Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.

Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.

Abstract: The invention provides methods, uses and compositions for the treatment of juvenile rheumatoid arthritis (JRA). The invention describes methods and uses for treating JRA, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to prevent flare-ups associated with JRA. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of JRA in a subject.

Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

Abstract: Disclosed herein are methods of reducing a symptom of respiratory disease in a pre-weaned milk-fed mammal by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Also included are methods of reducing mixing stress in human and non-human mammals by administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Further included are milk and food compositions including the interleukin-10 peptide or anti-interleukin-10 antibody.

Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-EL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.

Abstract: The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).

Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.

Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides methods of treating breast cancer using antibodies that bind to GPNMB, immunoconjugates and other derivatives thereof.

Abstract: A method of treating multiple sclerosis (MS) in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: 11, 15, 19, 23, 27 and 31, thereby treating MS in the subject.

Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Abstract: The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.

Abstract: There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, for use in the treatment of cancer in patients who have previously been treated for cancer and either not responded to said treatment or have previously responded to said treatment and subsequently relapsed.

Abstract: Described herein are methods for treating hematological malignancies and/or solid tumors in a subject using inhibitors of integrin alpha 6. In some embodiments, the inhibitors are monoclonal antibodies. The antibodies may be conjugated to additional therapeutic agents. The antibodies may be co-administered sequentially or simultaneously with additional therapeutic agents.

Abstract: The present invention relates to antibodies targeted to BDCA2 that deplete plasmacytoid dendritic cells (pDC) and methods of using the antibodies to treat disorders associated with pDC.

Abstract: Engineered multivalent and multispecific binding proteins that bind two different (e.g., nonoverlapping) epitopes of the same receptor or two different receptors expressed on the same cell are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.

Abstract: Antibodies are provided which specifically bind human and Macaca fascicularis lysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as LAMP1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The application further provides for the detection of LAMP1 gene amplification or gain in cancer cells leading to the determination if patients with cancer are likely to respond to anti-LAMP1 therapy.

Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.

Abstract: Provided are bivalent bispecific antibody comprising a first polypeptide comprising a first Fc fragment and a first single-domain antigen-binding (VHH) fragment and a second polypeptide comprising a second Fc fragment and a second single-domain antigen-binding (VHH) fragment, wherein the first VHH fragment has specificity to a tumor cell or a microorganism and the second VHH fragment has specificity to an immune cell, and wherein the first fragment is N-terminal to the second fragment.

Abstract: Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-?) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc* (NSG) mice with three different human cancers expressing WT1/HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis.

Abstract: The invention relates to a glycoprotein comprising an optionally fucosylated glycan according to formula (105) or (106), wherein Su(A)x is a modified sugar moiety comprising one or more functional groups A. Functional group A is independently selected from the group consisting of a thiol group, a halogen, a sulfonyloxy group, a halogenated acetamido group, a mercaptoacetamido group and a sulfonated hydroxyacetamido group. The invention also relates to a glycoprotein-conjugate wherein a glycoprotein according to the invention is conjugated to a molecule of interest. Said molecule of interest may for example be an active substance. The invention further relates to a process for the preparation of a modified glycoprotein, and to a method for the preparation of a glycoprotein-conjugate. The invention particularly relates to modified antibodies, antibody-conjugates, antibody-drug conjugates and methods for the preparation thereof.

Abstract: Chimeric antigen receptors that specifically bind to anaplastic lymphoma kinase are disclosed. Nucleic acids, recombinant expression vectors, host cells, antibodies, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.

Abstract: A resin composition includes a cellulose derivative, wherein a water absorption warp amount after a D2 test specimen obtained by injection-molding the resin composition using a mold of JIS type D2 regulated in JIS7152-3 (2005) is maintained for 24 hours on an aluminum plate in an environment of a temperature of 65° C. and a humidity of 85% RH is 0.3 mm or lower.

Abstract: A resin composition includes a cellulose derivative, wherein a saturated water absorption of the resin composition is in a range of 7% or greater.

Abstract: A resin composition includes a cellulose derivative in which at least one hydroxyl group is substituted with an acetyl group in an amount ratio of 90% by weight or greater with respect to a total amount of the resin composition, wherein a melt flow rate (MFR) of the resin composition is in a range of 10 g/10 min to 20 g/10 min.

Abstract: A resin composition includes a cellulose derivative, wherein a Hazen color number (APHA) of the resin composition is 50 or lower.

Abstract: A halogenated polysaccharide is provided having a halogen content of from about 1.0 wt. % to about 85 wt. % based on the total weight of the halogenated polysaccharide and having an average chain length of at least 6 monosaccharides. Methods of halogenating a polysaccharide to form a halogenated polysaccharide are provided that can be performed in the presence or absence of a proton solvent. Compositions such as articles of manufacture containing a halogenated polysaccharide and methods of producing such articles are also provided. The article of manufacture can also include one or more additional polymers, for example, polyvinylchloride (PVC). The article of manufacture can be, for example, a flooring tile, flooring plank, or carpet. Halogenated polysaccharides and products containing the same are bio-based, environmentally sustainable replacements or complements to existing polymers and polymer products.

Abstract: Cyclic carbonate azide having a structure according to the following formula (A) wherein R1-R5 are independently selected from the group consisting of hydrogen, C6-20 aryl, C7-36 aralkyl, and C1-30 alkyl groups; said aryl, aralkyl, and alkyl groups my optionally be substituted with heteroatoms, X is a hydrocarbon moiety having at least one carbon atom, T has the structure —N(R6)— or —O—, R6 is selected from the group consisting of hydrogen and C1-20 alkyl groups, optionally substituted with heteroatoms, k is 0, 1, or 2, m is 0 or 1, n is 0 or 1, p is 1 or 2, Z is an aliphatic or aromatic hydrocarbon moiety having at least one carbon atom, optionally substituted with heteroatoms, and Y is either (B) or C) or (D).

Abstract: The invention relates to a modified diene elastomer comprising predominantly the entity functionalized in the middle of the chain by an alkoxysilane group, optionally partially or completely hydrolysed to give silanol, bearing an epoxide function and the silicon atom of which bonds the two pieces of the chain, the chain ends of the modified diene elastomer being functionalized to at least 70 mol %, with respect to the number of moles of chain end, by an amine function.

Abstract: A urethane-functional (meth)acrylate monomer is provided that is defined by the formula where R1 is a monovalent organic group, R2 is a hydrogen atom or a monovalent organic group, and R3 is a hydrogen atom or an alkyl group. The urethane-functional (meth)acrylate monomer may be polymerized and advantageously provides improved mechanical properties such as tensile modulus, tensile strength and elongation-at-break tensile modulus, tensile strength and elongation-at-break.

Abstract: Disclosed are procatalyst compositions having an internal electron donor which include a substituted phenylene aromatic diester and optionally an electron donor component. Ziegler-Natta catalyst compositions containing the present procatalyst compositions exhibit high activity and produce propylene-based olefins with broad molecular weight distribution.

Abstract: The present invention relates to a continuous or semi-continuous freeze coagulation process for aqueous polymer dispersions, wherein said process comprises a freezing step and a solid-liquid separation step and is further characterized in that it comprises the further step of admixing water and/or water vapor between the freezing step and the solid-liquid separation step.

Abstract: A method to fabricate polyolefin polymer with hydroxyl functional group is taught. The method comprises following steps: (1) blending a polar solvent, an ?,?-alkyenol compound and a trialkyl halosilane compound to form an trialkyl-siloxane group protected co-monomer; (2) copolymerizing the trialkyl-siloxane group protected co-monomer with an ?-olefin monomer to form a copolymer with side chain trialkyl-siloxane group protectors in presence of a metallocene catalyst and co-catalyst mixture; and (3) hydrolyzing the copolymer with an acid to form the polyolefin polymer with at least one hydroxyl functional group.

Abstract: An acylated hydrocarbon polymer is aminated by reacting a primary or secondary aromatic amine which is solid at room temperature with an acyl group of the polymer, by: supplying a melt of the acylated polymer; supplying a solution of the aromatic amine in a polar aprotic solvent which has a boiling point of at least about 15° C., a melting point below about 40° C., and a dielectric constant of at least about 5° at 25° C.; mixing the solution at 140° C. to 185° C.; and cooling the resulting amine-reacted polymer with a liquid while retaining the polar aprotic solvent in the polymer.

Abstract: The present disclosure provides a process for producing propylene-based polymer. The process includes contacting, under polymerization conditions in a gas phase polymerization reactor, propylene monomer and optionally one or more comonomers with a Ziegler-Natta catalyst composition. The process includes maintaining the temperature of a reaction zone of the reactor at a temperature from greater than 72° C. to less than or equal to 85° C., and forming a propylene-based polymer having a molecular weight (Mw) greater than 100,000, and a Mz+1/Mz less than 2.20. The resultant propylene-based polymer is advantageous in fiber applications.

Abstract: The present invention relates to a supported hybrid catalyst and a method for preparing an olefin based polymer using the same. The supported hybrid catalyst according to the present invention can be used in the preparation of an olefin-based polymer, and the olefin-based polymer prepared using the supported hybrid catalyst has excellent processability and mechanical properties and thus can be effectively used for the application of films or the like.

Abstract: A film-forming auxiliary suitable for use in a resin emulsion such as a fluororesin emulsion used as a raw material for a coating material or the like, the film-forming auxiliary containing emulsion particle, a polymer constituting the emulsion particle being obtained by emulsion polymerization of a monomer component in which the content ratio of a (meth)acrylate having a ring structure is 20-70% by mass, and the film-forming auxiliary being excellent in each of low-temperature film-forming property, warm water resistance, extensibility, weather resistance, vertical-surface coating property and warm water freezing stability.

Abstract: Vulcanizable polymer compositions based on backbone-functionalized polydienes having the general formula (I):

Abstract: The present invention relates to a novel method for solvent-free preparation of a polymer of (meth)acrylic acid in solution, said polymer having a molecular weigh of less than 8,000 g/mol and a polydispersity index (PI) of 2 to 5 by radical polymerization.

Abstract: The present invention relates to a novel method for preparing a (meth)acrylic acid polymer in an aqueous solution, said polymer having a molecular mass lower than 8000 g/mol, for example using copper carbonate and iron sulphate (or the derivatives thereof).

Abstract: The present disclosure relates to the homopolymerization of terpenoids containing an alcohol functional group by free radical polymerization.

Abstract: A catalyst for olefin polymerization, comprising: (A-1) a bridged metallocene compound represented by the following Formula [1-1], and (b) at least one compound selected from: (b-1) an organoaluminum oxy compound, (b-2) a compound which forms an ion pair, and (b-3) an organoaluminum compound: wherein in Formula [1-1], R1, R2, R3, R4, R5, R8, R9, and R12 are each selected from a hydrogen, a hydrocarbon group and a silicon-containing group; the four groups of R6, R7, R10, and R11 are not hydrogen atoms, and are each selected from a hydrocarbon group or a silicon-containing group; R13 and R14 are each a hydrocarbon group or the like, excluding a hydrogen atom and a methyl group; M is Ti, Zr or the like; Y is carbon or the like; Q is a halogen or the like; and j is an integer from 1 to 4.

Abstract: This invention relates to a catalyst system comprising a half sandwich chromocene compound featuring a tethered P-donor, with an activator and optional supportation on silica which produces ethylene homopolymer or copolymer.

Abstract: The present invention is a process for producing copolymers of ethylene and alpha-olefins having from 4 to 10 carbon atoms in three polymerization stages where a low molecular weight copolymer of ethylene is produced in two of the stages and a high molecular weight copolymer in one of the stages. The resulting copolymers have a low content of extractable material and can be extruded to films which can be used in food contact applications.

Abstract: The present invention relates to an ethylene/1-hexene or ethylene/1-butene copolymer having excellent processibility. The ethylene/1-hexene or ethylene/1-butene copolymer according to the present invention has high molecular weight and wide molecular weight distribution, and thus excellent processibility, and has excellent environmental stress crack resistance, and thus, may be applied for a high inner pressure heating pipe, a mining pipe, or a large-diameter pipe, and the like.